Clinical Report: Considering Interventional Glaucoma Management
Overview
Revise to accurately reflect the role of genetic testing without overstating its impact on treatment intensity.
Background
Glaucoma is a leading cause of irreversible blindness worldwide, making effective management crucial. Traditional reactive approaches often delay intervention until significant damage has occurred. The shift towards proactive interventional strategies, including laser treatments and genetic assessments, represents a significant advancement in glaucoma care.
Data Highlights
No numerical data available in the article.
Key Findings
- Genetic testing can identify patients at risk for aggressive glaucoma, allowing for earlier intervention.
- The LiGHT Trial demonstrated that selective laser trabeculoplasty (SLT) provides long-term disease control and reduces the need for medications and surgeries.
- Minimally invasive glaucoma surgery (MIGS) offers effective IOP reduction with a high safety profile and rapid recovery.
- FDA-approved sustained-release medications, such as Durysta and iDose TR, provide extended IOP control.
- Optometrists in 14 states can now perform in-office laser procedures, expanding access to treatment.
Clinical Implications
Healthcare providers should consider early interventional strategies, such as SLT and MIGS, as first-line treatments for glaucoma. Additionally, genetic testing can enhance patient education and adherence to follow-up care, ultimately improving outcomes.
Conclusion
The evolution of glaucoma management towards interventional techniques underscores the importance of early treatment to preserve vision and enhance patient quality of life. Continued advancements in this field are expected to further improve patient care.
Related Resources & Content
- Schweitzer, J., Optometric Management, 2025 -- Considering Interventional Glaucoma Management
- Consensus Builds for Interventional Glaucoma, Glaucoma Physician, 2025
- Video: Spotlight on Interventional Glaucoma, Glaucoma Physician, 2025
- Viewpoint from the Editor: The Interventional Glaucoma Trifecta, Ophthalmology Management, 2025
- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines - PubMed
- Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines - PubMed
- Ocular hypertension due to ocular surgery (Concept Id: C5852667) - MedGen - NCBI
- Polygenic Risk Scores for Glaucoma Onset in the Ocular Hypertension Treatment Study - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.


